Nivolumab and Relatlimab-rmbw - Mechanism of Action, Indications, Dosage, and Adverse Drug Reactions

What Is Nivolumab and Relatlimab-rmbw?

Nivolumab and Relatlimab-rmbw are used together to treat advanced melanoma. Nivolumab and Relatlimab are administered in a fixed-dose combination. When used in conjunction, Relatlimab and Nivolumab offer a dual checkpoint inhibition approach that strengthens the immune system's capacity to fight cancer cells in patients with advanced melanoma (skin cancer).

Is Nivolumab and Relatlimab-rmbw FDA Approved?

The U.S. Food and Drug Administration (FDA) approved Relatlimab-rmbw and Nivolumab together on March 18, 2022. Patients 12 years of age and older with advanced melanoma (skin cancer) are treated with this fixed-dose combination of monoclonal antibodies.

Drug Group

Relatlimab and Nivolumab belong to the monoclonal antibody drug class. Nivolumab is a PD-1-blocking antibody that targets the inhibitory checkpoint protein PD-1 (programmed death receptor-1).

The LAG-3 (lymphocyte activation gene-3) protein, another checkpoint receptor, is the target of Relatlimab, an antibody that blocks LAG-3.

Indications

A combination of Relatlimab, a blocking antibody targeting lymphocyte activation gene-3 (LAG-3), and Nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, is recommended for the treatment of adult and pediatric patients with unresectable or metastatic melanoma aged 12 years or older.

Dosage Forms and Available Strengths

The single-dose vial injection of 240 mg (milligrams) of Nivolumab and 80 mg of Relatlimab per 20 mL or milliliters (12 mg and 4 mg per mL).

Warnings and Precautions

Immune-Mediated Adverse Reactions:

• The term "immune-mediated adverse reactions" refers to a group of adverse reactions that can affect any organ system or tissue and have the potential to be severe or fatal. These reactions include pneumonitis (lung inflammation), colitis (colon inflammation), hepatitis (liver inflammation), immune-mediated endocrinopathies (conditions resulting from the immune system's reaction to anti-cancer medications, specifically immune checkpoint inhibitors), adverse reactions in the dermatologic system, renal dysfunction-causing immune-mediated arthritis (joint inflammation), and myocarditis (heart muscle inflammation).

• Look for prompt detection and handling. Assess thyroid function, liver enzymes, and creatinine at baseline and regularly during therapy.

• Depending on the nature and intensity of the response, withhold or permanently stop.

Infusion-Related Reactions:

Depending on the severity of the reaction, stop Nivolumab and Relatlimab-rmbw temporarily, reduce the infusion pace, or stop it entirely.

Allogeneic Hematopoietic Stem Cell Treatment Complications:

Patients with allogeneic stem cell transplantation before or after receiving PD-1 or PD-L1 blocking antibody treatment may experience fatal and other severe consequences.

Embryo-Fetal Toxicity:

Relatlimab and Nivolumab may be harmful to the fetus. Women should be advised about the potential risks to the fetus and the need to use effective contraception during treatment to lower the risk of pregnancy.

For Patients

How Do Nivolumab and Relatlimab-rmbw Work?

• These medicines help your immune system fight cancer more effectively.

• Nivolumab works by removing a “brake” on your T-cells (your immune system’s soldiers), letting them spot and attack cancer cells.

• Relatlimab-rmbw targets LAG-3, giving your immune system an extra boost.

• When you take these medicines together, your immune system may be stronger at fighting melanoma than if you took either one alone.

What Are the Benefits of Nivolumab and Relatlimab-rmbw?

• Immunotherapy medicines like Nivolumab and Relatlimab-rmbw help the body’s immune system fight advanced melanoma.

• Nivolumab helps immune cells find and attack cancer by blocking PD-1. Compared to chemotherapy, it often helps people live longer and usually has fewer serious side effects. Some people continue to feel better even after treatment stops.

• When used together, these medicines can help slow the cancer and improve results. However, everyone responds differently, so it is important to talk to a doctor about the best treatment for you.

How Are Nivolumab and Relatlimab-rmbw Administered?

• You will get the medicines through an IV (intravenous infusion).

• Adults and children weighing at least 88 pounds usually get 480 mg of Nivolumab and 160 mg of Relatlimab every four weeks.

• The infusion takes about 30 minutes.

• Your medical team will handle preparation and dosing, and they may adjust it if you experience side effects.

What Are the Side Effects of Nivolumab and Relatlimab-rmbw?

Some side effects are mild:

• Feeling weak or tired.

• Muscle aches.

• Headaches.

• Loss of appetite.

Some side effects can be serious. Call your doctor immediately if you notice:

• Trouble breathing or a worsening cough.

• Coughing up blood.

• Chest or stomach pain.

• Blood in your stool or dark, sticky stool.

• Sudden fatigue, chills, or unusual sweating.

• Rapid heart rate.

• Mood changes, confusion, or memory problems

• Numbness, tingling, or burning in your hands or feet

• Fever, rash, or hair thinning

• Yellowing of your skin or eyes, or dark urine

• Painful sores in your mouth, nose, or genitals

If you notice anything unusual, contact your doctor right away.

What Are the Things to Inform the Doctor Before Taking Nivolumab and Relatlimab-rmbw?

Before starting treatment, inform your doctor about:

• Any allergies to medicines, foods, or other substances.

• All medications, vitamins, or supplements you take.

• If you have had organ transplants or autoimmune diseases like lupus, Crohn’s disease, or ulcerative colitis.

• Any lung, thyroid, kidney, or liver problems.

• If you are pregnant or planning to become pregnant, you should avoid pregnancy during treatment and for at least five months after. Your doctor can help you choose safe birth control.

• If you are breastfeeding or planning to breastfeed, do not do so during treatment and for five months after your last dose.

Diet:

Eat as usual unless your doctor gives you specific advice.

Missed Dose:

Contact your doctor to reschedule if you miss an appointment.

Overdose:

If too much medicine is given, contact your doctor or emergency services immediately.

Storage and Handling:

• The medicine is usually stored in the hospital or clinic.

• Keep it refrigerated at two degrees Celsius to eight degrees Celsius (35.6 degrees Fahrenheit to 46.4 degrees Fahrenheit), do not freeze.

• Keep it in the original packaging, away from light and children.

• Open vials can be kept at room temperature for up to 72 hours.

• Dispose of any leftover solution safely; don’t reuse it.

For Doctors

What Are the Pharmacological Aspects of Nivolumab and Relatlimab-rmbw?

Pharmacodynamics:

The safety and effectiveness of Nivolumab and Relatlimab-rmbw exposure-response relationship and pharmacodynamic response time course have not been fully characterized. Patients should be informed about the potential for immune-mediated and infusion-related side effects, problems associated with allogeneic hematopoietic stem cell transplantation, and embryo-fetal damage.

Mechanism of Action:

The combination of Nivolumab (anti-PD-1) and Relatlimab (anti-LAG-3) results in greater T-cell activation than either antibody alone. During studies, it was observed that LAG-3 blockade potentiates the anti-tumor activity of PD-1 blockade, inhibiting tumor growth and promoting tumor regression.

Pharmacokinetics

Absorption:

According to pharmacokinetic studies, Nivolumab appears to exhibit linear pharmacokinetics, with dose-proportionate increases in peak concentration and AUC (area under the curve).

Relatlimab levels in the body were studied in cancer patients who received Nivolumab and Relatlimab-rmbw at different doses and schedules, either alone or with Nivolumab. The drug reached a stable level in the body after about 16 weeks when given every four weeks. Over time, Relatlimab built up in the body to about double its initial level.

At doses of 160 mg or higher every four weeks, the concentration of Relatlimab in the blood increased in proportion to the dose. With the recommended dose, the highest and average blood levels of Relatlimab were about 62 µg/mL and 29 µg/mL, respectively. For Nivolumab, the highest and average levels were about 187 µg/mL and 94 µg/mL.

Distribution:

It has been observed that the volume of distribution at a steady state of Relatlimab is 6.6 litres (20 percent) and 6.6 litres (19 percent) of Nivolumab.

Excretion:

At steady state, Relatlimab is cleared from the body at an average rate of 5.5 mL per hour, about 10 % slower than after the first dose. Its effective half-life when given as Nivolumab and Relatlimab-rmbw is about 26 days, meaning it stays in the body for several weeks.

Nivolumab is cleared at about 7.6 mL/h at steady state, which is about 21 % slower than after the first dose. Its half-life is also about 26.5 days, showing that both drugs remain in the body for a similar length of time.

Drug Interactions

Some of the drugs that interact with Nivolumab and Relatlimab-rmbw include:

• Betamethasone.

• Budesonide.

• Cortisone.

• Deflazacort.

• Dexamethasone.

• Efgartigimod alfa.

• Hydrocortisone.

• Idelalisib.

• lenalidomide

• Methylprednisolone.

• Pomalidomide.

• Prednisolone.

• Prednisone.

• Rozanolixizumab.

• Thalidomide.

• Triamcinolone.

Clinical Studies

The purpose of the clinical trial was to assess the efficacy of Nivolumab and Relatlimab-rmbw, a Nivolumab-based therapy for stage III or IV melanoma that has spread or is incurable. 714 participants who had previously had melanoma therapy were enrolled in the trial. Nivolumab 480 mg was given to patients in a randomized fashion every four weeks until the disease progressed or the toxicity was intolerable.

Progression-free survival (PFS) was the primary efficacy outcome; overall survival (OS) and overall response rate (ORR) were the other metrics. Twelve weeks after randomization, tumor assessments were performed. The trial population comprised 58 percent men. According to the study, patients randomized to the Nivolumab and Relatlimab-rmbw arms showed a statistically significant improvement in PFS.

Use in Specific Populations

• Pregnancy:

When given to a pregnant woman, Nivolumab and Relatlimab-rmbw, an intravenous injection that contains Relatlimab and Nivolumab, may be harmful to the fetus. When Nivolumab was administered to monkeys, there was a rise in abortions and early infant mortality. The consequences of pregnancy are probably more pronounced in the second and third trimesters. Pregnant women's Nivolumab and Relatlimab-rmbw are not well documented.

• Breastfeeding:

Patients should refrain from breastfeeding while receiving Nivolumab and Relatlimab-rmbw, or for at least 5 months after the final dose, due to limited information on Nivolumab and Relatlimab's effects on human milk and milk production.

• Pediatric Use:

Nivolumab and Relatlimab-rmbw have comparable safety and efficacy to adult treatments for pediatric patients with metastatic or unresectable melanoma who are 12 or older. A suggested dosage has not yet been determined for juvenile patients weighing less than 88.18 pounds and younger than 12 years.

• Geriatric Use:

The safety and efficacy of Nivolumab and Relatlimab-rmbw treatment in studies did not significantly differ between younger and elderly patients.